Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety

(2019) Alan K. Davis et al.   AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE

Cessation and reduction in alcohol consumption and misuse after psychedelic use

(2019) Albert Garcia-Romeu et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory

(2019) Leor Roseman et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption

(2018) Alan K Davis et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

(2018) Leor Roseman et al.   Frontiers in Pharmacology

Predicting Responses to Psychedelics: A Prospective Study

(2018) Eline C. H. M. Haijen et al.   Frontiers in Pharmacology

Long-lasting subjective effects of LSD in normal subjects

(2017) Yasmin Schmid et al.   PSYCHOPHARMACOLOGY

Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens

(2016) José Carlos Bouso et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

(2016) Theresa M Carbonaro et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

(2016) Frederick S Barrett et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

(2016) Roland R Griffiths et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

(2016) Stephen Ross et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Alterations of consciousness and mystical-type experiences after acute LSD in humans

(2016) Matthias E. Liechti et al.   PSYCHOPHARMACOLOGY

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

(2015) Michael P Bogenschutz et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations

(2015) Michael Kometer et al.   PSYCHOPHARMACOLOGY

LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects

(2014) Peter Gasser et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Measuring insight through patient self-report: An in-depth analysis of the factor structure of the Birchwood Insight Scale

(2014) Sean D. Cleary et al.   PSYCHIATRY RESEARCH

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

(2011) Katherine A MacLean et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

(2011) Roland R. Griffiths et al.   PSYCHOPHARMACOLOGY

Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV)

(2010) Erich Studerus et al.   PLoS One

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

(2008) RR Griffiths et al.   JOURNAL OF PSYCHOPHARMACOLOGY